XBIO vs BLIN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

XBIO

29.6
AI Score
VS
BLIN Wins

BLIN

63.8
AI Score

Investment Advisor Scores

XBIO

30score
Recommendation
SELL

BLIN

64score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric XBIO BLIN Winner
Revenue 1.47M 11.75M BLIN
Net Income -1.39M -986,000 BLIN
Net Margin -94.5% -8.4% BLIN
Operating Income -1.47M -1.07M BLIN
ROE -22.8% -11.1% BLIN
ROA -19.9% -6.4% BLIN
Total Assets 6.97M 15.33M BLIN
Current Ratio 7.43 0.61 XBIO

Relative Price Performance (Last 90 Days)

XBIO 1M: +33.7% · 3M: +22.1% BLIN 1M: -18.7% · 3M: +7.8%

Current Technical Phase

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 74

RSI (14): 73.6 · Price: $3.59

BLIN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 37

RSI (14): 36.5 · Price: $0.99

Fundamentals Snapshot

Metric XBIO BLIN
Market Cap
Forward P/E -10.0 8.3
Trailing P/E
Revenue (TTM)
Revenue Growth 0.1% 0.0%
Gross Margin 1.0% 0.7%
Operating Margin -1.5% -0.1%
EPS -1.16 -0.10
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BLIN is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.